Clinical Trials · NCT00332969
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 25
- Start date
- Sep 2005
- Locations
- 1 site, Germany
- Primary endpoint
- Shrinkage of tumor size and diameter of 3 respectively 6 months